Amgen rolls toned-down TV ad for cholesterol-fighting Repatha by Beth Snyder Bulik Monday, April 22, 2019 Amgen lightens the mood in a new TV ad for cholesterol med Repatha even as Amgen continues a patent dispute and price drops for the drug.
11. Amgen by Arlene Weintraub After two straight years at number 12 on FiercePharma’s list of the top pharma companies by revenues, Amgen moved up one spot with 2018 sales of $23.75 billion.
Jury backs Amgen's PCSK9 patents, puts Sanofi on defense again by Tracy Staton Tuesday, February 26, 2019 Give the latest round of the PCSK9 patent fight to Amgen. A jury backed two key patents that Sanofi and Regeneron have admitted they infringed.
Despite 35 price hikes, Sanofi’s net prices fell again in 2018 by Eric Sagonowsky Thursday, February 21, 2019 Sanofi raised list prices on 35 of 76 drugs in 2018, but its net prices fell an average of 8%.
Regeneron, Sanofi cut Praluent list tag 60% to match Repatha by Angus Liu Monday, February 11, 2019 After launching at about the same price—$14,000-plus—Praluent and Repatha again stand on par. But this time, it’s less than half the original sticker.
On heels of new price cuts, Amgen's Repatha hits wall at SCOTUS by Arlene Weintraub Wednesday, January 9, 2019 Amgen failed to keep Repatha rival Praluent off the market with a patent challenge, but it's hoping more price cuts will help it grab market share.
Express Scripts ramps up list-price pressure with new formulary by Eric Sagonowsky Tuesday, November 13, 2018 Express Scripts is rolling out a new formulary to assist drugmakers with lowering list prices.
For sale: Amgen chops 60% off Repatha's list price by Eric Sagonowsky Wednesday, October 24, 2018 It's common for drugmakers to offer behind-the-scenes rebates to win coverage for their drugs. But Amgen's big retail price cut is a rare move.
Sanofi, Regeneron closes in on sales-boosting CV nod by Tracy Staton Wednesday, September 12, 2018 Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.
Amgen asks Supreme Court to take up PCSK9 patent spat by Eric Sagonowsky Thursday, August 9, 2018 Amgen's aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the market didn't work, but the big biotech hasn't given up.
